Organon (OGN) Retained Earnings (2020 - 2026)
Organon (OGN) posted quarterly Retained Earnings of -$539.0 million for Q1 2026, down 152.53% year-over-year from $1.0 billion in Q1 2025, and down 148.6% on a QoQ basis from $1.1 billion in Q4 2025.
Organon (OGN) Retained Earnings (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Retained Earnings for 7 consecutive years, with -$539.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 152.53% year-over-year to -$539.0 million; the TTM figure through Mar 2026 stood at -$539.0 million (down 152.53% YoY), while the FY2025 annual figure was $1.1 billion, up 270.88% from the prior year.
- Retained Earnings came in at -$539.0 million for Q1 2026 at Organon, down from $1.1 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.3 billion in Q3 2025, with the low at -$649.0 million in Q4 2024.
- Average Retained Earnings over 5 years is -$28.9 million, with a median of -$529.0 million recorded in 2022.
- Across the five-year window, Retained Earnings tumbled 3468.75% in 2024 and soared 330.82% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$564.0 million in 2022, then soared by 178.55% to $443.0 million in 2023, then slumped by 246.5% to -$649.0 million in 2024, then soared by 270.88% to $1.1 billion in 2025, then slumped by 148.6% to -$539.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$539.0 million, $1.1 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 29.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -14.83 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -17.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.67 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | -539.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -539.00 Mn |
| Dec 31, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | -649.00 Mn |
| Sep 30, 2024 | -571.00 Mn |
| Jun 30, 2024 | -612.00 Mn |
| Mar 31, 2024 | -577.00 Mn |
| Dec 31, 2023 | 443.00 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -25.00 Mn |
| Mar 31, 2023 | -534.00 Mn |
| Dec 31, 2022 | -564.00 Mn |
| Sep 30, 2022 | -383.00 Mn |
| Jun 30, 2022 | -551.00 Mn |
| Mar 31, 2022 | -529.00 Mn |
| Dec 31, 2021 | -513.00 Mn |
| Sep 30, 2021 | -493.00 Mn |
| Jun 30, 2021 | 81.00 Mn |